Another important aspect for STAT1β being the more successful key marker in tumor defense than STAT1α is the fact that STAT1β acts as a dominant negative regulator in IFNγ signaling [38] and that the best characterized signaling axis for PD-L1 is its induction mediated by IFNγ [1]. This evidence concerns the gene CD274 and neoplasm.